For direct compression campaigns in a tableting suite, the pharmaceutical-grade (S)-ethyl 3-cyano-5-methylhexanoate is first passed through a conical mill fitted with a 610 µm round screen and an impeller speed of 1,500 rpm. The milled powder is blended with silicified microcrystalline cellulose and pregelatinized starch in a bin blender at 12 rpm for 25 minutes. Flow behavior is evaluated under USP<1174>; unmilled lots within this ester-API class frequently show a Hausner ratio above 1.35, and the addition of colloidal silicon dioxide at 0.8% w/w reduces the angle of repose to below 38° in pilot batches. Compression is carried out on a rotary tablet press equipped with 10 mm round concave punches and a main compression force bracketed between 8 kN and 18 kN. The ester functionality imposes a narrow processing window: if residual moisture by USP<921> exceeds 0.5% w/w, punch filming and sticking appear at the tablet face after approximately 20 minutes of production-press operation. Blend uniformity samples are collected in accordance with 21 CFR 211.110 and analyzed by HPLC; acceptance is set at 90.0–110.0% of label claim with relative standard deviation below 5.0% for the active. Finished tablets are tested for weight variation under USP<905>, and dissolution is profiled under USP<711> Apparatus 2 at 50 rpm in 900 mL of pH 4.5 acetate buffer maintained at 37°C ± 0.5°C. Since the compound is hydrophobic, a surfactant may be required in the medium under ICH Q6A; however, media selection must be justified by solubility data in the release method validation. Tablet hardness is maintained between 50 N and 90 N to avoid friability failure under USP<1216> and to prevent prolonged disintegration in fasted-state oral administration.

How Does Powder Flooding Arise in Tamping-Pin Capsule Filling at Low Packing Fraction?

Powder-in-capsule processing for (S)-ethyl 3-cyano-5-methylhexanoate becomes viable only after the milled API is pre-blended with lactose monohydrate to raise the bulk density above 0.45 g/cm³. The powder blend is loaded into a Bosch GKF 720 tamping-pin capsule filler with 5 dosing stations and 0.3 mm pin-to-pin compression settings. Tamping pin penetration depth is set from 12 mm to 16 mm, and station compression force is limited to 60–120 N because the API’s low cohesive strength leads to powder flooding when the packing fraction drops below 0.35. Fill weight is controlled at 250 mg ± 5% for size 0 HPMC capsules with a shell moisture content of 4–8% w/w. The compliance sequence includes uniformity of dosage units under Ph. Eur. 2.9.40 and USP<905>; dissolution is run under USP<711> Apparatus 1 at 75 rpm in 900 mL of pH 6.8 phosphate buffer. A processing boundary appears at relative humidity above 60%; at this point the API picks up surface moisture and begins to adhere to the rear wall of the dosing chamber, producing split capsule bodies and reject rates above 2.0%. Batch records require environmental logging of the packaging suite at 20–25°C and 35–45% RH. The finished capsule product is sealed in alu-alu blisters to limit hydrolysis from external moisture ingress.

High-Shear Granulation Process Limits and Moisture Endpoints

Aqueous high-shear granulation is selected when direct compression cannot deliver adequate content uniformity for a low-dose tablet formulation. The dry mix, consisting of the API at 10–15% w/w, mannitol 55–65% w/w, crospovidone 3–5% w/w, and hypromellose 2% w/w, is charged into a GEA PMA 65 high-shear granulator. An impeller speed of 150 rpm and a chopper speed of 1,500 rpm are used during dry blending for 3 minutes. The granulation fluid is a 0.1 M citrate buffer at pH 4.5 containing dissolved povidone K30 at 5% w/v. The pH of the granulating fluid is held between 4.0 and 5.0 because the ester group undergoes base-catalyzed hydrolysis above pH 6.5; wet massing beyond 5 minutes raises free water and produces agglomeration that cannot be recovered by dry milling. Granules are discharged through a 4 mm perforated grate and transferred to a Glatt GPCG 5 fluid-bed dryer. Inlet air temperature is controlled at 50°C, while product temperature is kept between 28°C and 32°C. Drying continues until loss on drying by USP<731> is 1.0–2.0% w/w; drying below 1.0% produces brittle granules that fracture during downstream compression, while above 2.0% the ester-containing API begins to adhere to the mill screen. The dried granules are passed through a 1.0 mm conical mill, then lubricated with magnesium stearate at 0.5% w/w for 3 minutes. Particle size is verified by USP<786>; the target fraction retained below 840 µm and above 150 µm should account for at least 75% of the mass. Tablets compressed from this granule show matching dissolution profiles to the direct compression batch when granule porosity is controlled within an envelope of 15–25%. The terminal product is a film-coated immediate-release tablet; the coating is applied at 2–3% w/w in a perforated pan at 35°C exhaust temperature to avoid heat-induced ester degradation.

When Aseptic Injectable Processing Requires Co-Solvent Selection

Injectable formulation development for (S)-ethyl 3-cyano-5-methylhexanoate starts from aqueous solubility bracketing in water for injection. In the absence of a published monograph, a conservative threshold of 2 mg/mL is used as the trigger for co-solvent screening. The compound shows pH-dependent low aqueous solubility; therefore, a co-solvent system is screened using polyethylene glycol 300 and propylene glycol under ICH Q8 design-of-experiment principles. A representative development formulation contains the API at 5 mg/mL, PEG 300 at 30% v/v, propylene glycol at 10% v/v, and 5 mM acetate buffer at pH 5.0 made with water for injection. The bulk solution is compounded in a jacketed stainless steel vessel at 4–8°C, sparged with nitrogen to limit oxidative degradation, and mixed with a magnetic-driven bottom impeller at 250 rpm for 30 minutes. The solution is filtered through a 0.45 µm prefilter and then through a 0.22 µm polyethersulfone membrane under 1.5 bar pressure. Aseptic filling is conducted in a Class 5 environment according to EU GMP Annex 1 and ISO 14644-1. Terminal steam sterilization at 121°C for 15 minutes is not generally applied because the ester linkage can undergo hydrolytic degradation under autoclave conditions; if a D-value of 1.0 minute or lower is demonstrated for the active, terminal sterilization may be acceptable, but published data for this specific configuration are limited. Injectables are tested for particulate matter under USP<788>: for small-volume injections, not more than 6,000 particles ≥ 10 µm and 600 particles ≥ 25 µm per container. pH is measured under USP<791> and must remain within 0.2 pH units of the target during storage at 2–8°C for 24 months. The finished injectable solution is a single-dose parenteral presentation, and container closure integrity is assessed under USP<1207> as part of stability.

Because granule stick-pack lines segregate low-density API during hopper transfer, suction filling of oral granules is conducted only after density equilibration in a bin blender at 10 rpm for 15 minutes. The granule formulation is manufactured by fluid-bed spray granulation: a dispersion of the API at 10–20% w/w in purified water containing hypromellose 5% w/w and sodium citrate 1.0% w/w is sprayed onto a microcrystalline cellulose seed bed at 1.5–2.5 g/min per kg of bed material. The inlet air temperature is set at 55°C, the product temperature is kept at 30°C, and the dew point of the process air is held below 4°C to avoid moisture-induced hydrolysis of the ester group. Granules are dried to a moisture endpoint of 1.0–1.5% w/w by USP<921>, screened through a 500 µm sieve, and filled into single-dose stick packs on a Romaco Siebler HM 1/140 vertical form-fill-seal machine. Fill weight is set at 1.0 g ± 3%, with an individual stick pack moisture vapor transmission rate below 0.5 g/m²/day to preserve stability. Uniformity of dosage units is assessed under USP<905>, and dissolution is performed with USP<711> Apparatus 2 at 50 rpm in 900 mL of pH 4.5 acetate buffer. The terminal dosage form is an orally administered single-dose granule for reconstitution or direct administration; the granule surface is coated with a thin ethylcellulose film at no more than 2% w/w to mitigate organoleptic burden associated with the hydrophobic API without altering release kinetics.

Freeze-Dried Injection Formulation Requires Controlled Nucleation and Collapse Temperature Profiling

When solution-state hydrolysis of (S)-ethyl 3-cyano-5-methylhexanoate exceeds the assigned degradation threshold during short-term stability, the injectable dosage form is converted to a freeze-dried solid in a 10 mL Type I glass vial. The fill solution contains the API at 10 mg/mL, mannitol at 4.0% w/v as a crystalline bulking agent, and sodium acetate at 5 mM to control pre-lyophilization pH at 5.0. The solution is filtered through a 0.22 µm membrane and filled into vials to a fill volume of 2.0 mL, then partially stoppered with bromobutyl closures. The lyophilization cycle in a production freeze dryer includes shelf cooling to -45°C at 0.5°C/min, a nucleation hold at -45°C for 180 minutes, and primary drying at a shelf temperature of -20°C with a chamber pressure of 100 mTorr for 36 hours. Because the collapse temperature for this specific formulation has not been reported in open compendial literature, the shelf temperature is kept at least 10°C below the conservative glass transition temperature of the frozen matrix; published data for this specific configuration are limited. Secondary drying is carried out at +30°C for 6 hours to reduce residual moisture to below 0.5% w/w by USP<921>. The freeze-dried cake is tested for reconstitution time in water for injection at 20–25°C; complete dissolution must occur within 3 minutes with gentle swirling. The reconstituted solution is tested for clarity, particulate matter under USP<788>, and pH under USP<791>. Container closure integrity is verified by vacuum decay under USP<1207>; the vial is sealed under a nitrogen headspace with an oxygen content below 1.0%.